Gradual occlusion of coronary arteries may result in reversible loss of cardiomyocyte function (hibernating myocardium), which is amenable to therapeutic neovascularization. The role of myocardin-related transcription factors (MRTFs) co-activating serum response factor (SRF) in this process is largely unknown. Here we show that forced MRTF-A expression induces CCN1 and CCN2 to promote capillary proliferation and pericyte recruitment, respectively. We demonstrate that, upon G-actin binding, thymosin 4 (T4), induces MRTF translocation to the nucleus, SRF-activation and CCN1/2 transcription. In a murine ischaemic hindlimb model, MRTF-A or T4 promotes neovascularization, whereas loss of MRTF-A/B or CCN1-function abrogates the T4 effect. We further show that, in ischaemic rabbit hindlimbs, MRTF-A as well as T4 induce functional neovascularization, and that this process is inhibited by angiopoietin-2, which antagonizes pericyte recruitment. Moreover, MRTF-A improves contractile function of chronic hibernating myocardium of pigs to a level comparable to that of transgenic pigs overexpressing T4 (T4tg). We conclude that MRTF-A promotes microvessel growth (via CCN1) and maturation (via CCN2), thereby enabling functional improvement of ischaemic muscle tissue.
C hronic ischaemic disease of the heart or peripheral muscle is currently treated by surgical or interventional efforts to revascularize the stenosed or occluded vascular networks. However, within a growing patient population, conventional therapeutic strategies are exhausted and clinical benefit is expected from adjuvant neovascularization therapies (angiogenesis/arteriogenesis). Previous preclinical 1 and clinical studies 2 failed to demonstrate a gain of perfusion when enforcing angiogenesis (capillary growth) in the absence of microvessel maturation-that is, recruitment of pericytes and smooth muscle cells 3, 4 . Moreover, arteriogenesis (collateral growth), an essential element of flow improvement, did not prolong walking time in patients with critical limb ischaemia, when auxiliary granulocytemacrophage colony-stimulating factor treatment was employed without induction of microvessel growth and stabilization 5 . In contrast, adaptive collateralization 6 occured when a proangiogenic factor such as vascular endothelial growth factor A (VEGF-A) was combined with the maturation factors plateletderived growth factor-B 1 or Angiopoietin-1 (ref. 7) . On the other hand, inhibition of NFkB signalling, impairing VEGF-A and platelet-derived growth factor-B expression, led to a hyperbranched and immature collateral network 8 . Thus, an increase in stable and regulated microvessels is required to induce functional neovascularization.
Myocardin-related transcription factors (MRTFs) have been shown to activate serum response factor (SRF) [9] [10] [11] upon dissociation from G-actin 12 , providing muscle growth and regeneration 13, 14 . SRF is co-activated by myocardin 15 or MRTFs A and B 16 . These SRF coactivators are interacting with G-actin and translocate to the nucleus 17 , when G-actin levels decrease, for example, due to sequestration by the G-actinbinding peptide thymosin 4 (T4) [18] [19] [20] . Since T4 is a potent pro-angiogenic factor 21 , an involvement of the T4-MRTF-SRF axis in vascular growth would require transcriptional activation beyond well-known myogenic proteins 13, 14 . However, MRTF coactivaton of SRF induces pro-angiogenic factors such as CCN1 (Cyr61) 22 and maturation factors such as connective tissue growth factor (CTGF) 23, 24 . Moreover, SRF controls tip cell behaviour in angiogenesis 25, 26 , indicating a role of MRTF-SRF in vascular growth and maintenance.
In the current study, we sought to investigate the capability of MRTF-A and its upstream activator, T4, to induce functional vascular regeneration after prolonged ischaemia. We found that both T4 as well as MRTF-A increase the SRF-dependent genes CCN1 and CCN2, and induce capillary growth and maturation in vivo. Of note, the microvascular alterations were followed by adaptive collateralization in rabbit hindlimb ischaemia and porcine chronic hibernating myocardium. In the latter model we could demonstrate that both, perfusion and function of the ischaemic myocardium, improve upon T4 or MRTF-A overexpression.
Results

T4
and MRTF-A induce CCN1 and CCN2 in vitro. We found ( Fig. 1a-d ) that MRFT-A induced hallmarks of angiogenesisthat is, migration and tube formation of cultured human microvascular endothelial cells-to a similar extent as T4. The pro-angiogenic effect of MRTF-A was dependent on the G-acting-binding motif of T4, as mutating this domain and annihilating G-acting binding abolished the T4 effect on vessel growth, as did a short-hairpin RNA (shRNA) interfering simultaneously with MRTF-A and B transcription (MRTF-shRNA) 27 . Consistently, T4 enhanced nuclear MRTF-A translocation (Fig. 1e, Supplementary Fig. 1a,b) , as well as transcription of an MRTF/SRF-dependent reporter gene containing three SRF-binding sites of the c-fos promoter (p3DA.Luc, Fig. 1f) 28 . Both, MRTF-A and T4, induced expression of genes involved in microvessel growth, most notably CCN1, mediating angiogenesis 29 and CCN2, relevant for 10T1/2 pericyte-like cell attraction 24 ( Supplementary Fig. 1c-g ). Of note, T4 transfection did not affect MRTF-A content ( Supplementary Fig. 1h ), unlike MRTF-A transfection. In line with CCN1/2 being downstream of MRTFs and relevant for vessel formation, interference with CCN1-shRNA prevented T4-induced tube formation (Fig. 1g) , whereas CCN2-shRNA interrupted attachment of a murine pericyte-like cell line (C3H/10T1/2) to endothelial tubes in vitro (Fig. 1h-i) .
Role of MRTFs in Thymosin ß4-induced neovascularization.
To further demonstrate the relevance of MRTF signalling in vivo, we used a murine hindlimb ischaemia model. Intramuscular (i.m.) injection of recombinant adeno-associated virus (AAV) vectors (rAAVs, Supplementary Fig. 2a-c ) raised tissue concentration of target proteins in the treated limb (Fig. 2a) and transcript levels of the downstream mediators CCN1 and CCN2 (Fig. 2b, Supplementary Fig. 2d-f) . Consistently, rAAV.MRTF-A induced capillary growth (Fig. 2c,d ) and increased perfusion at d7 (Fig. 2e,f) . As an upstream activator, T4 had a similar effect on vessel growth and function ( Fig. 2c-f ), unless the G-actin-binding motif was lacking (T4 m) or an rAAV.MRTF-shRNA was coapplied. To further assess the relevance of MRTFs in T4-induced vessel growth, rAAV.Cre was applied to Mrtf-a À / À Mrtfb flox/flox hindlimbs in order to cause MRTF-A and -B double deficiency. In Cre-induced MRTF-A/B knockouts, T4 was unable to stimulate capillary growth (Fig. 2g) , pericyte recruitment ( Supplementary  Fig. 2g ,h) and improve perfusion (Fig. 2h, Supplementary Fig. 2i ) at d7 after ischaemia induction. Similarly, when rAAV.Cre was applied to CCN-1 flox/flox mice, hindlimbs did not display T4-mediated gains of either capillaries (Fig. 2i,j) or perfusion at d7 (Fig. 2k,l) . Thus, MRTF-A transduction or MRTF activation via T4-mediated G-actin sequestration stimulate transcription of CCN1 to mediate functional vascular regeneration.
MRTFs induced pericyte recruitment and collateral growth. The interdependence of microcirculatory growth and arteriogenesis for the mediation of flow recovery was assessed in a rabbit ischaemic hindlimb model ( Supplementary Fig. 3a) , which is compatible with topic separation of the microvessel growth area (lower limb) and the collateralization area (upper limb). Regional transduction of the ischaemic calf muscles with MRTF-A or T4 via rAAV (Fig. 3a, Supplementary Fig. 3b-d ) led to functional neovascularization including CD31 þ capillary sprouting, NG2 þ pericyte investment (Fig. 3b-d ) and collateral growth (Fig. 3e,f) . Of note, MRTF activation via T4 transduction of the thigh region, although capable of inducing a modest collateral growth, did not increase perfusion, whereas restricting MRTF activation via T4 to the calf region sufficed to significantly stimulate microand macrovascular growth as well as perfusion ( Supplementary  Fig. 3e-i) . Detachment of microvascular pericytes by forced Angiopoietin-2 expression (Fig. 3b-d ) abrogated the T4-and MTRF-A-mediated collateralization and flow improvement ( Fig. 3e-g ). Moreover, blocking flow-induced vasodilation by oral application of L-NAME, an unselective nitric oxide synthase inhibitor, did not affect capillary growth and maturation ( Supplementary Fig. 3j ) but prevented collateral formation and increased perfusion ( Supplementary Fig. 3k-l) . Thus, nitric oxide appears to provide collateral growth upon microcirculatory growth and maturation. This observation is complemented by the finding that direct T4 injection into the area of collateral growth (upper limb) does not improve perfusion to the same extent as remote injection of rAAV.T4 into the lower limb, the site of microcirculatory growth ( Supplementary Fig. 3e-i) . These findings indicate that microvessel maturation and nitric oxide signalling are processes that have to occur in the sequence of MRTF-A-mediated vascular growth in order to accomplish functional vascular regeneration.
Efficacy of MRTF-A resolving hibernating myocardium. Although peripheral and coronary arteries both perfuse muscle tissue, a unique feature of the heart muscle is its permanent contractile activity that requires continuous oxygen supply. A chronic decrease in oxygen supply alters the cellular composition of viable cardiomyocytes in the ischaemic area, resulting in a regional loss of contractile force called hibernating myocardium 30, 31 . Inside cardiomyocytes, hallmarks of hibernating myocardium are reduced myofilaments 32 and mitochondria content as well as an increased glycogen content 33 . Here we studied the potential of MRTF-A to resolve dysfunction in hibernating myocardium because of percutaneous implantation of a reduction stent in pig hearts 34 inducing gradual occlusion of the Ramus Circumflexus (RCx, Supplementary Fig. 4a ). At d28 after rAAV.MRTF-A application into the ischaemic area, significantly increasing MRTF-A tissue content ( Supplementary  Fig. 4b ), we found a significantly higher degree of capillary density and pericyte coverage (Fig. 4a-c) . Collateral growth and perfusion under rapid pacing (130 min À 1 ) were still impaired at d28-that is, before LacZ-and MRTF-A transduction ( Supplementary Fig. 4c-f) -but improved at d56-that is, 4 weeks after MRTF-A-, and not LacZ transduction (Fig. 4d-f) .
Enhanced collateral perfusion ( Supplementary Fig. 4g ) generated an improved functional reserve of the ischaemic area at rapid pacing (130 and 150 beats per minute, Fig. 4g ). Concomitantly, we found an improved ejection fraction (EF) as marker of global systolic function (Fig. 4h , dynamic examples in Supplementary  Fig. 4 and Supplementary video 1,2) and a decrease in the left Supplementary Fig. 4i ), a prognostic marker of beginning heart failure.
Transgenic pigs ubiquitously and constitutively overexpressing T4 ( Supplementary Fig. 5 ) displayed similar capillary growth and maturation as rAAV-MRTF-A-treated animals ( Fig. 4a-c) . At d56, the blood flow reserve in the ischaemic area was increased (Fig. 4f) , and functional reserve of either the ischaemic region ( Fig. 4g ) or the whole heart ( Fig. 4h ) was enhanced as in rAAV.MRTF-A-treated hearts. Of note, by virtue of the constitutive T4 overexpression already from days 0 to 28, T4tg animals did not experience a significant loss of perfusion nor myocardial function at rest or under rapid pacing (Fig. 4g , Supplementary Fig. 4d-g,i) .
Moreover, rAAV.T4-induced micro-and macrovascular growth and subsequent increases in perfusion reserve were abrogated, when an inhibitory MRTF-A-shRNA was co-applied ( Fig. 5a-g ). The gain of global (Fig. 5h , dynamic examples in Supplementary video 3,4) and regional myocardial function (Fig. 5i ) was abolished when T4 transduction was combined with MRTF-A inhibition by a suitable shRNA.
Discussion
Here using a combined genetic and physiological approach in mouse, rabbit and pig models, we show that MRTFs stimulate growth and maturation of microvessels as well as increased collateral blood flow upon arterial occlusion in hindlimb and coronary networks. Mechanistically, we demonstrate that MRTF translocation downstream of T4 coactivates SRF inducing CCN1/CCN2 resulting in augmented angiogenesis and vascular smooth muscle cell recruitment and formation of functional vessels that can carry collateral flow (Fig. 6 ).
Of note, the relevance of the Thymosin4/MRTF-A/SRF pathway for microcirculatory growth was demonstrated, since deletion of CCN1, a gene induced by this transcriptional pathway, abrogated the gain of vascular structures and function in vivo. Moreover, in rabbit and pig models, we extend this notion to the formation of collaterals upon microcirculatory growth, a property not universal to vascular growth factors.
A key feature of MRTF-A activation is nuclear translocation upon reduction in G-actin levels, and nuclear export when G-actin abundance increases 10, 35 . Forced expression of MRTF-A 
Cre), the increase of capillary/muscle fibre ratio was abolished (PECAM-1 staining, scale bar: 100 mm), as was the gain of hindlimb perfusion (k,l). (All error bars: mean ± s.e.m., n ¼ 5, *Po0.05, **Po0.001, using ANOVA with the Student-Newman-Keul's procedure).
or T4, a peptide activating MRTF-A by G-actin binding (Fig. 1) , initiates an orchestrated micro-and macrocirculatory growth response in case of chronic peripheral (Figs 2 and 3) and heart ( Fig. 4 ) muscle ischaemia. Consistently, chronic dysfunction of hibernating pig myocardium was resolved by either direct MRTF-A overexpression or MRTF-A activation via T4 (Fig. 4) . The notion that MRTF-A-SRF signalling provides myofilaments is of particular interest since a loss of actin cytoskeleton is a hallmark of hibernating myocardium caused by chronic coronary hypoperfusion 32 . Thus, MRTF-A is located at the crossroads of myocyte and vessel regeneration in hibernating myocardium. T4, the most abundant G-actin-binding peptide of the cytosol, is capable of inducing vessel growth via endothelial migration and sprouting 21, 36 . An essential role of MRTF-A in T4 angiogenic signalling was established in vitro and in vivo, since MRFT-AshRNA was capable of abrogating endothelial migration and sprouting (Fig. 1b,d ) as well as micro-and macrovascular growth (Fig. 2d,f) and functional cardiac improvement ( Supplementary  Fig. 6 ). Accordingly, endothelial-specific deficiency of MRTFs caused incomplete formation of the primary vascular plexus of the developing retina 26 . Moreover, SRF, the main target of MRTF-A, has recently been identified as crucial for tip cell behaviour in sprouting angiogenesis upon VEGF-A stimulation 25 . Nevertheless, VEGF-A results in growth of immature and unstable capillaries 37 , as opposed to T4-MRTF-A, pointing to a difference in signalling of both vessel growth factors.
A particular feature of the T4-MRTF-A-SRF signalling axis is the balanced nature of vascular growth-that is, microvessel growth and maturation as well as adaptive collateralization. Surprisingly, angiopoietin-2 not only abrogated pericyte investment after MRTF-A-or T4 treatment (Fig. 3b,c) but also compromised adaptive collateralization (Fig. 3e-g ). Thus, microcirculatory maturation appears to be essential for the transmission of collateral growth signals. The role of the microvascular compartment is additionally underscored by the observation that local i.m. treatment of the collateral compartment (upper limb in rabbits) does not provide an equivalent vascular regeneration to local i.m. treatment of the microvascular compartment (lower limb, Supplementary Fig. 3g-i ). An essential signal, sent from the microvascular compartment to induce adaptive collateral growth, appears to be nitric oxide, since the unselective nitric oxide synthase inhibitor L-NAME abrogated the arteriogenic effect of T4. Of note, L-NAME did not affect capillary sprouting nor ARTICLE pericyte to endothelial cell ratio in T4-treated hindlimbs ( Supplementary Fig. 3j-l) . These experiments indicate a hierarchical order in the balanced vascular growth process induced by the T4-MRTF-A-SRF axis, which originates in the microvasculature and progresses to subsequent adaptive collateralization.
Collectively, our data demonstrate that activation of T4-MRTF augments collateral blood flow in ischaemic heart and hindlimb via induction of CCN1/CCN2. At the cellular level this response involves endothelial sprouting via CCN1 (CYR61) 29 and maturation-that is, pericyte investment-via CCN2 (CTGF) 24 resulting in a stable and functional vascular network that can carry collateral blood flow and improve conductance. Pericyte investment is crucial herein since Ang 2, by virtue of disrupting pericyte investment 38 , abolished the positive effects exerted by T4-MRTF signalling (Fig. 3) . This finding indicates the central role of vessel maturation and balanced vessel growth and paves new therapeutic avenues towards functional neovascularization.
Methods
Reagents. All cell culture media and chemicals were purchased from Sigma (Deisenhofen, Germany) if not indicated otherwise. Contrast agent Solutrast 370 was provided by Byk Gulden (Konstanz, Germany). CCN1-shRNA (Cyr61-shRNA, sc-39332) and CCN2-shRNA (CTGF-shRNA, sc-39329) were purchased from Santa Cruz Biotechnology, CA, USA.
Adeno-associated viral vectors. The recombinant rAAV.MRTF-A, rAAV.T4, rAAV.T4m, rAAV.LacZ, rAAV.Cre and rAAV.MRTF-shRNA (5 0 -GATCCCCG CATGGAGCTGGTGGAGAAGAATTCAAGAGATTCTTCTCCACCAGCTCCA TGTTTTTGGAAA-3 0 ) vectors were produced using triple transfection of U293 cells. One plasmid encoded the transgene under control of a CMV promoter flanked by cis-acting AAV2 internal terminal repeats, a second plasmid provided AAV2 rep and AAV9 cap in trans 39 , whereas a third plasmid (delta F6) supplemented adenoviral helper function. Cells were harvested 48 h later and vectors purified with caesium gradients 40 . Viral titres were determined using RT-PCR against the polyA tail of the vector bGH (primer sequence see Table 1 ). Trans and helper plasmids were kindly provided by James M. Wilson, University of Pennsylvania.
Cell culture. Satisfection (TPP AG, Trasadingen, Schweiz) was used for the transfection of human microvascular endothelial cells (HMECs, CDC, North Carolina, USA), murine endothelial cells (bEnd.3, CRL-2299, ATCC, USA) and myocytic cell line (HL-1 cells, kindly provide by Dr W. Claycomb) according to the manufacturer's instructions. Here 100 ml serum-and antibiotic-free DMEM medium were mixed with 3 ml Satisfection transfection agent. In vitro tube formation and coculture experiments. For matrigel experiments, HMECs were transfected with pcDNA, MRTF-A, T4±MRTF-shRNA (5 0 -GATC CCCGCATGGAGCTGGTGGAGAAGAATTCAAGAGATTCTTCTCCACCAG CTCCATGTTTTTGGAAA-3 0 ), T4 m (which lacked the G-actin-binding motif KLKKTET) 41 or T4±CCN1-shRNA. Cells (8,000 cells per well) were seeded on matrigel (BD Matrigel Basement Membrane Matrix, BD Biosciences, USA) in basal endothelial growth medium with an 5% fetal bovine serum addition and pictures were taken after 18 h. Number of rings per low-power field was quantified.
In coculture experiments, HL-1 cells were transduced by a rAAV-T4 ± CCN1-shRNA, rAAV.MRTF-shRNA or rAAV-T4 m (1 Â 10 6 AAV6 particles per cell). HL-1 and matrigel-embedded HMECs (8,000 cells per well) were physically separated by a permeable membrane. After 18 h, HL-1 cells were removed and ring formation per low-power field was quantified.
Pericytic CH3/10T1/2 cell (CCL-226, ATCC, USA) attraction to murine endothelial cells (bEnd.3) was assessed after transfecting the endothelial compartment with pcDNA, MRTF-A or T4 ± CCN2-shRNA using Satisfection (Agilent, Boeblingen, Germany). Endothelial cells were stained DiD (red, Vybrand) and seeded on matrigel (12,000 cells per well). After 6 h DiO (green, Vybrand)-stained pericyte-like cells (2,000 cells per well) were added and migration towards tubes was allowed for 2 h. Then, coculture pictures were taken using confocal laser microscopy (Carl Zeiss, Jena, Germany).
Migration assay. HMEC cells were transfected with the indicated transgenes, as described above. A total of 60,000 cells were grown to confluence in wells carrying a strip-like insert (ibidi, Munich, Germany). After 24 h, the insert was removed. Images were taken at the time points 0 and 22 h at a 10-fold magnification (low-power field), and the uncovered area analysed (Image J 1.43u, National Institute of Health (NIH), USA) HL-1 cell staining. Cardiomyocytic HL-1 cells were transduced by AAVs encoding for the indicated transgenes. Then, cells were plated on m dishes (ibidi). After 48 h, nuclei were stained with Syto62. After fixation of the cells with PFA (2%), they were permeabilized and incubated with an MRTF-A antibody (1:200, Santa Cruz Biotechnology) and a secondary antibody (1:200, Alexa 488, Invitrogen, Karlsruhe, Germany). Pictures were taken using confocal laser microscopy (Carl Zeiss), and the mean fluorescence intensity of the area of 100 nuclei, identified via Syto62, was automatically assessed with its LSM5 image browser.
High-performance liquid chromatography (HPLC) analysis. The determination of T4 was performed via HPLC analysis 42 . Briefly, tissue samples were destructed by adding 4 M perchloric acid containing 1% Thiodiethanol to a final concentration Mixtures were homogenized, incubated at 4°C for 30 min and centrifuged for 10 min at 20,000 g. The supernatant was analysed using reverse-phase chromatography. In rabbits, endogenous and exogenous T4 were distinguished by detection of the rabbit-specific T4-Ala.
Luciferase assay. For determining the MRTF-dependent luciferase activity, HMEC and HL-1 cells were transfected with p3DA.Luc, an SRF reporter gene (a construct of a synthetic promoter with three copies of the c-fos SRF-binding site and a Xenopus type 5 actin TATA box plus a transcription start site inserted into pGL3 ¼ p3DA.Luc) 43 and 930 ng of either pcDNA, T4 or a T4 mutant lacking the G-actin-binding site. Comparable transfection efficacy was assured by co-transfection of 50 ng ptkRL (Renilla luciferase reporter). Cell pellets were lysed, further purified by centrifugation for 10 min at 4°C and 13,000 r.p.m. and utilized for assessment of firefly luciferase activity and Renilla luciferase activities, which are given as ratio firefly luciferase/renilla activity 43 .
RNA modulation and detection. Real-time (RT-)-PCR was performed with SYBR green dye (iQ SYBR Green supermix, Bio-Rad, Munich, Germany) and measured on an iQ-Cycler (Bio-Rad). RT-PCR was performed with primers mentioned in Table 1 . Expression levels were normalized to GAPDH and displayed as fold change to the pcDNA control situation. The comparative 2-DDC t method was carried out, calculating the delta C t values for the gene of interest and the housekeeping gene and then calculating the difference between both delta C t values 44 .
Western blot analysis MRTF-A. For analysis of total MRTF-A protein, cell culture and tissue samples were homogenized in 1 ml lyses buffer containing 20 mM Tris, 1 mM EDTA, 140 mM NaCl, 1% Nonidet P-40 (NP-40), 0.005 mg ml À 1 leupeptin, 0.01 mg ml À 1 aprotinin, 1 mM PMSF, pH 7.5. Whole protein extracts (60 mg) were resolved on 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). After electrophoresis, the proteins were electrotransferred to a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA), blocked with 5% nonfat milk in PBS-0. Biotechnology) was incubated and the membrane was developed with a chemiluminescence reagent (ECL, Detection Reagents, GE Healthcare, Buckinghamshire, UK). For analysis of the nuclear versus the cytosolic MRTF-A protein content, separation was performed with the Ne-Per nuclear and cytoplasmatic extraction reagents (Thermo Scientific, Rockford, IL, USA) according to the manufacturer's instructions. After that western blot analysis was performed, as described above. As control protein either alpha Tubulin (6A204, 1:500, Santa Cruz Biotechnology) or for the nuclear fraction Lamin B1 (ZL-5, 1:500, Santa Cruz Biotechnology) was used. Full-length images of immunoblots are shown in Supplementary Fig. 6 .
Animal experiments. Animal care and all experimental procedures were performed in strict accordance to the German and NIH animal legislation guidelines and were approved by the Bavarian Animal Care and Use Committee (AZ 55.2-1-54-2531-26/09, 130/08, 140/07). All animal experiments were conducted at the Walter Brendel Centre of Experimental Medicine.
Murine hindlimb ischaemia. Unilateral hindlimb ischaemia of the right leg 45 was performed in male age-matched C57Bl6 mice (6-8 weeks of age, Charles River, Sulzfeld, Germany) as well as in
rAAV.cre) and CCN1 fl/fl mice as well as CCN1 À / À Vi mice ( ¼ CCN1 fl/fl ±rAAV.cre), generated in the laboratory of Ralf Adams, presented unpublished). Before induction of ischaemia (day À 14), 3 Â 10 12 rAAV virus particles were applied intramuscularly to the right leg as indicated 46 . On day 0 the left leg underwent sham operation, whereas the femoral artery was ligated in the right leg. The post-ischaemic blood flow recovery was conducted using laser doppler flow cytometry (Moor Instruments, Devon, UK). Measurements were assessed directly before and after surgery, as well as on days 3 and 7. Results are given as right to left leg ratio including subtraction of background tissue value. RT-PCR and HPLC analyses were performed on day 5 after ischaemia induction; tissue was harvested from treated and non-treated legs. Analyses of capillary density and vessel maturation were performed on day 7 in all groups via PECAM-1 (sc1506, 1:50, Santa Cruz Biotechnology) and NG-2 (in MRTF-A þ / À B fl/fl mice, 1:200, Chemicon, Nürnberg, Germany) staining in frozen tissue samples of the musculus gastrocnemius and musculus adductor.
Rabbit hindlimb ischaemia. In female rabbits, 2-2.5 kg body weight, on day 0 the complete femoral artery of the right leg was excised 44 and rAAV application (5 Â 10 12 virus particles) was performed via i.m. injection into the right limb as indicated. On days 7 and 35, angiography was performed by injection of contrast agent (Solutrast 370, Byk Gulden) into the ischaemic limb with an automatic injector (Harvard Apparatus, Freiburg, Germany). Furthermore, fluorescent microspheres (15 mm, Molecular Probes, Eugene, OR, USA) were applied for blood flow measurements in the ischaemic and non-ischaemic tissues. For blood flow analysis, tissue samples were digested as described earlier. 1, 47 Fluorescence analysis was performed via Tecan Saphire 2 microplate reader for the emission wavelengths 680, 638, 598, 545, 515, 468 and 424 nm, depending on the fluorescent colour used. Blood flow is given as percentage day 7, right to left leg 48 . Analyses of capillary density and vessel maturation were performed via PECAM-1 (sc1506, 1:50, Santa Cruz Biotechnology) and NG-2 (1:200, Chemicon) staining in frozen tissue samples (lower limb only) of the ischaemic and non-ischaemic limbs.
Pig chronic myocardial ischaemia. Three-month-old, male pigs were anaesthetised and arteria carotis communis as well as vena jugularis externa are instrumented 49 . Briefly, a PTFE membrane-covered restrictor stent was implanted in the proximal RCx, leading to a 75% reduction in blood flow. Correct localization of the stent and patency of the distal vessel was ensured by injection of contrast agent 49 Regional myocardial function. On day 56, after induction of ischaemia, sternotomy was performed and ultrasonic crystals were placed subendocardially in the non-ischaemic area (LAD control region) as well as in the ischaemic area (Cx perfused area) in a standardized manner. Subendocardial segment shortening (Sonometrics) was assessed at rest and under increased heart rates (functional reserve, pacing 130 and 150 bmp) and evaluated offline (electrocardiogramdependent).
Regional myocardial blood flow. Analysis of the regional myocardial blood flow was performed on day 28 (before rAAV treatment) and day 56 (28 days after rAAV treatment) via fluorescent microspheres (Molecular Probes). The microspheres (15 mm, 5 Â 10 6 particles per injection) were injected via a pigtail catheter into the left ventricle. Blood flow measurements were performed at rest and under increased heart rate (130 bpm). Fluorescence content was analysed via Tecan Saphire 2 micro plate reader and calculation of the regional myocardial blood flow was performed, either as ml g À 1 tissue absolute or as the ratio to the nonischaemic region at rest (blood flow % non-ischaemic) 1, 50 .
Histology. Tissue samples of the ischaemic and non-ischaemic areas were analysed for capillary density (PECAM-1-positive cells, red) and pericyte investment (NG2-positive cells, green). Staining for capillaries was performed with a CD31 (PECAM-1)-antibody (1:200, SC1506, Santa Cruz Biotechnology) and a Rhodamin-labelled secondary antibody (1:50, SC2092, Santa Cruz Biotechnology), whereas the vessel maturation was quantified by pericyte (NG2 antibody, 1:200, AB5320 Millipore) co-staining. Pictures of the ischaemic and non-ischaemic regions were taken with high-power field magnification (40-fold) and five independent pictures per region (ischaemic and non-ischaemic) and per animal were quantified.
rAAV transduction efficacy. For evaluation of the rAAV transduction efficacy, the control mice, rabbit and pigs were treated with rAAV.LacZ. Cryosections of the LacZ-transduced animals were performed and stained for beta-galactosidase (blue staining). Furthermore, RT-PCR for the different transgenes was performed using the primers described in Table 1 and was analysed as described above.
Tomato mice. These mT (membrane-targeted tdTomato)/mG (membranetargeted enhanced green fluorescent protein) homozygous expressing mice (Jackson Laboratory, Bar Harbor, ME, USA) carry loxP sites on both sides of the mT and mG encoding sequence. Cre expression via rAAV.cre for virus transduction efficacy deleted the mT (red fluorescence) in the cells and allowed for eGFP expression (green fluorescence) in the same cells ( Supplementary Fig. 2b ).
Statistical methods. The results are given as mean values±s.e.m. Statistical analysis for comparison of two groups was performed with Student's t-test. Statistical analyses for multiple comparisons were performed using one-way analysis of variance. Whenever a significant effect was obtained (Po0.05), we used multiple comparison tests between the groups with the Student-Newman-Keul's procedure (IBM SPSS 19.0, IBM Chicago, IL, USA). Differences between groups were considered significant for Po0.05.
